Pittsburgh, Aug. 23, 2021 (GLOBE NEWSWIRE) — Ariel Precision Medicine, Inc., a privately held biotechnology company developing innovative solutions for complex chronic disease, announced the appointment of Professor David C. Whitcomb, M.D. Ph.D. as chief scientific officer (CSO). Professor Whitcomb is a pioneer in the use of mathematics, genetics, genomics, cell biology, neurosciences, immunology and epidemiology to study complex inflammatory disorders and cancer risks of the digestive system. He co-founded Ariel Precision Medicine along with Jessica M. Gibson in 2015 and since that time has served on the board of directors, as chair of the Medical Advisory Board and as a technical and scientific consultant.
As CSO of Ariel Precision Medicine Dr. Whitcomb will utilize his experience and insights as a physician, scientist and innovator to oversee the scientific and translational functions of the company, which aims to improve the efficiency and effectiveness of physician diagnosis and care plans, improve patient outcomes and quality of life and reduce unnecessary costs.
“Professor Whitcomb is among the most-cited authors in the field of pancreatic diseases with multiple landmark papers,” stated Ms. Gibson, CEO of Ariel Precision Medicine. “His innovations in precision medicine continue to be studied and emulated by other leading programs throughout the world. He has been an important member of our team of advisors for many years and we are excited to welcome him into the executive team as our chief …
Full story available on Benzinga.com